Optical Coherence Tomography Characterization of Shockwave IVL for Treatment of Calcified Coronary Lesions

Patient-level Pooled Analysis of the Disrupt CAD OCT Sub-studies

Ziad A. Ali, MD DPhil

Department of Cardiology, St. Francis Hospital & Heart Center Roslyn, New York



Disclosure Statement of Financial Interest

DISRIPT

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship	Company
Consulting Fees	Abbott Vascular Inc
Consulting Fees	Boston Scientific Corporation
Consulting Fees	Shockwave Medical
Stock Shareholder/Equity	Shockwave Medical



Individual Patient-data Pooled Analysis

Disrupt CAD I-IV: OCT Sub-studies

	CADI	CAD II	CAD III	CAD IV	Pooled		
Enrollment	Dec 2015 – Sep 2016	May 2018 – Mar 2019	Jan 2019 – Mar 2020	Nov 2019 – Apr 2020	Dec 2015 – Apr 2020		
Study design	Prospective, multi-center, single-arm						
ITT (N)	60 ¹	120 ³	3844	64 ⁵	628 ⁶		
OCT Analysis [*] (N)	28 ²	57	106†	71†	262		
OCT core laboratory	Cardiovascular Research Foundation						
Target lesions	Severely calcified*, de novo coronary artery lesions						
Target lesion RVD	2.5mm – 4.0mm						
Target lesion stenosis	≥50% and <100%	≥50% and <100%	≥70% and <100%	≥70% and <100%			

*Patient enrollment in OCT sub-studies was open to all sites participating in the Disrupt CAD studies that routinely perform OCT imaging. †Includes patients from the roll-in cohort.

Consistent OCT core laboratory evaluation across all OCT sub-studies



¹Brinton et al. Circulation 2019;139:834-836, ²Ali et al. J Am Coll Cardiol Img 2017;10:897-906, ³Ali et al. Circ Cardiovasc Interv 2019;12:e008434, ⁴Hill et al. J Am Coll Cardiol 2020;76:2635-46, ⁵Saito et al. Circ J 2021;85(6):826-33, ⁶Kereiakes et al., J Am Coll Cardiol Intv 2021;14:1337-48

Baseline Clinical & Lesion Characteristics

Characteristic	N = 248	Core Lab Ana	alysis	N = 248
Age, yrs	72 ± 9		LAD	67.3%
Male, %	77 1	Target vessel	LCx	7.7%
		laiget vessei	RCA	24.2%
Diabetes meilitus, %	37.8		LM	0.8%
Hyperlipidemia, %	84.0	Reference vess	el diameter, mm	3.0 ± 0.5
Hypertension %	00.0	Minimum lumer	n diameter, mm	1.1 ± 0.4
	83.2	Diameter steno	sis	63.2 ± 11.5%
Prior MI, %	24.0	Lesion length, r	nm	25.8 ± 11.3
Prior CABG, %	57	Calcified length	, mm	42.8 ± 21.2
	0.7	Severe calcifica	ation	98.4%
Renal insufficiency	22.1	Bifurcation lesion		31.5%

CRF^{*}

Procedural Characteristics

Characteristic	OCT Pooled N=262
Procedure time, min	70 ± 24
Contrast volume, ml	207 ± 75
Pre-dilatation	34%
IVL catheters per patient	1.4 ± 0.8
Max IVL inflation pressure	6.0 ± 0.6
IVL balloon to artery ratio	1.3 ± 0.2
Pulses delivered	87 ± 51
Post-IVL dilatation	9%
Stents placed per patient	1.3 ± 0.5
Post-stent dilatation	96%

SCRF[™]
TCT

Visible Calcium Fracture Characteristics



Average of 3.2 fractures per lesion demonstrated by OCT

CRF^{*}

MLA Not Co-located with Pre-Procedural Max Calcium Site

Pre-IVL Post-IVL Post-Stent Lumen Area: 8.91mm² Lumen Area: 3.81mm² Lumen Area: 5.72mm² Stent Area: 8.44mm²



Lesion Characteristics and Stent Deployment Outcomes

	Pre-IVL N=248	Post-stent N=245
MLA, mm ²	2.1 ± 1.0	$6.2 \pm 1.9^{*}$
Area stenosis @MLA site, %	72 ± 12	18 ± 20
Calcium arc @max calcium site, °	270 ± 81	
Calcium thickness @max calcium site, mm	0.96 ± 0.25	
MSA, mm²		6.0 ± 1.9
Mean stent area, mm ²		7.9 ± 2.3
Stent expansion @max calcium site, %		103 ± 29
Mean stent expansion, %		107 ± 29
Any malapposition strut, %		3.9 ± 4.6

CRF[™]
 CR

*MLA was never co-localized with the pre-IVL maximum calcification

Predictors of Stent Expansion

Variable	Regression coefficient (95%CI)	p-value
Number of visible calcium fractures × fracture length	-0.26 (-1.36, 0.85)	0.65
Max calcium thickness at max continuous calcium site	5.25 (-9.54, 20.04)	0.49
Max superficial continuous calcium arc	-0.03 (-0.09, 0.03)	0.38
Length of continuous calcium ≥270°	0.61 (-0.97, 2.20)	0.45
Circumferential (360°) calcium	3.93 (-9.43, 17.30)	0.56
Number of pulses	0.06 (-0.01, 0.14)	0.11
Balloon to artery ratio [*] , per 0.1	4.51 (2.57, 6.45)	<0.0001
Maximum balloon pressure [*] , atm	-0.28 (-1.74, 1.18)	0.71

*Balloon to artery ratio and maximum balloon pressure derived from the largest post-dilatation or stent balloon used during the procedure.

CRF^{*}

Good stent expansion achieved regardless of calcium burden or visible calcium fracture

Final Angiographic and 30-day Clinical Outcomes

Core Lab Assessment	OCT Pooled N=262	CEC Adjudicated	OCT Pooled N=262
Final in-stent diameter stenosis	12.2 ± 6.8%	30-d MACE	4.6%
Acute gain, mm	1.6 ± 0.4	Cardiac death	0.0%
		All MI	4.6%
Any serious angiographic complications	0.0%	NQWMI	4.6%
Perforation	0.0%	Q-wave MI	0.0%
Abrupt closure	0.0%	TVR	0.4%
Slow flow	0.0%	Target lesion failure	4.6%
No reflow	0.0%	Stant thrombosis (definite or	
Distal embolization	0.0%	probable)	0.4%

Safety of IVL treatment in calcified coronary lesions

🛠 CRF

Conclusions

- The present individual patient data pooled analysis of 4 studies (N=262) represents the largest evaluation of IVL by OCT
- No serious angiographic complications were observed confirming the safety of IVL for the treatment of severely calcified coronary lesions
- OCT demonstrated extensive calcium fracture after IVL treatment with excellent stent expansion of severely calcified lesions
- Visible calcium fracture and calcium characteristics were not predictors of stent expansion following treatment with IVL



OCT Characterization of Eccentric Versus Concentric Calcium Treated with Shockwave IVL



Angiographic Lesion Characteristics

Core Lab	o Analysis	≤ 180° N=56	181° - 270° N=56	271° - 359° N=51	360° N=66	P value
	LAD	66.1%	75.4%	64.7%	68.2%	0.62
Target	LCx	8.9%	1.8%	9.8%	6.1%	0.27
vessel	RCA	23.2%	21.1%	25.5%	25.8%	0.93
	LM	1.8%	1.8%	0.0%	0.0%	0.59
Referenc	e vessel diameter, mm	2.9 ± 0.5	3.0 ± 0.5	2.9 ± 0.5	3.1 ± 0.5	0.26
Minimum	lumen diameter, mm	1.1 ± 0.4	1.1 ± 0.4	1.1 ± 0.4	1.1 ± 0.4	0.93
Diameter	stenosis	61.4 ± 10.9%	62.9 ± 12.8%	61.3 ± 12.3%	62.8 ± 10.5%	0.93
Lesion lei	ngth, mm	24.3 ± 10.1	24.8 ± 9.1	25.6 ± 13.3	27.9 ± 11.4	0.24
Calcified	length, mm	35.3 ± 19.4	44.6 ± 18.7	42.8 ± 20.2	49.9 ± 23.0	0.002
Severe ca	alcification	96.4%	100%	100%	98.5%	0.45
Bifurcatio	n lesion	32.1%	24.6%	35.3%	31.8%	0.66



Pre-IVL OCT Characteristics

Core Lab Analysis	≤ 180° N=56	181° - 270° _{N=56}	271° - 359° _{N=51}	360° N=66	<i>P</i> value
Minimum lumen area, mm ²	2.0 ± 1.1	2.1 ± 1.0	2.0 ± 0.8	2.1 ± 0.9	0.85
Area stenosis, %	72.4 ± 10.5	70.1 ± 11.2	72.7 ± 10.3	73.1 ± 12.5	0.24
Max continuous calcium arc*, °	131.1 ± 30.4	225.3 ± 27.3	309.3 ± 23.6	360.0 ± 0.0	<0.0001
Calcium index, ° × mm	1660 ± 803	3069 ± 1074	3794 ± 1423	5522 ± 2291	<0.0001
Max calcium thickness, mm	0.93 ± 0.27	0.92 ± 0.21	1.01 ± 0.27	0.97 ± 0.25	0.21
Min calcium thickness, mm	0.41 ± 0.13	0.35 ± 0.13	0.28 ± 0.14	0.27 ± 0.13	<0.0001

*Continuous calcium angle was defined as the maximum uninterrupted calcium angle observed in the lesion and was used to define the category assignment.

CRF^{*}

Divided into ~quartiles based on maximum continuous calcium angle

Procedural Characteristics

Core Lab Analysis	≤ 180° N=56	181° - 270° _{N=56}	271° - 359° _{N=51}	360° N=66	<i>P</i> value
Procedure time, min	70.1 ± 31.1	65.8 ± 31.6	67.6 ± 30.0	69.7 ± 31.9	0.87
Contrast volume, ml	215.5 ± 89.6	198.1 ± 76.4	208.5 ± 68.6	206.6 ± 65.8	0.68
Pre-dilatation, %	21.4%	29.8%	25.5%	39.4%	0.15
IVL catheters per patient	1.3 ± 0.6	1.4 ± 0.9	1.5 ± 0.8	1.5 ± 0.6	0.47
Max IVL inflation pressure	6.0 ± 0.3	6.0 ± 0.6	6.0 ± 0.8	6.0 ± 0.6	0.92
IVL balloon to artery ratio	1.3 ± 0.2	1.2 ± 0.2	1.3 ± 0.2	1.3 ± 0.2	0.87
Pulses delivered	86.6 ± 44.6	87.8 ± 60.6	83.3 ± 49.8	90.9 ± 38.1	0.91
Post-IVL dilatation, %	3.6%	8.8%	5.9%	10.6%	0.47
Stents placed per patient	1.3 ± 0.5	1.3 ± 0.6	1.4 ± 0.6	1.4 ± 0.5	0.80
Post-stent dilatation	94.6%	98.2%	96.1%	98.5%	0.57

SCRF[™]
TC1

Similar procedural approach across calcium angle quartiles

Consistent Outcomes in Eccentric and Concentric Calcium





Impact of IVL Treatment in Eccentric Calcification



Good luminal gain following IVL treatment (continuous calcium angle: <180°)

CRF'

Impact of IVL Treatment in Concentric Calcification



Good luminal gain following IVL treatment (continuous calcium angle: 181° to 270°)

CRF'

Impact of IVL Treatment in 360° Coronary Calcification



Good luminal gain following IVL treatment (continuous calcium angle: 360°)

CRF

Increased Calcium ⇒ Increased Visible Fracture







Consistent MSA and Stent Expansion Regardless of Visible Fracture



OCT may not detect subtle micro-fractures in calcific plaque

CRF

Micro-fracture Visualization by MicroCT



OCT may not detect subtle micro-fractures in calcific plaque

CRF^{*}

Virmani R., CVPath Institute

Post-stent OCT outcomes

Core Lab Analysis	≤ 180°	181° - 270°	271° - 359°	360°	P value
Minimum lumen area [*] , mm ²	6.1 ± 2.1	6.1 ± 1.9	6.2 ± 1.8	6.4 ± 1.9	0.78
Acute lumen gain at MLA site, mm ²	4.1 ± 1.7	4.0 ± 1.6	4.2 ± 1.6	4.4 ± 1.8	0.73
Mean lumen area, mm ²	8.1 ± 2.6	8.1 ± 2.1	8.2 ± 2.3	8.7 ± 2.2	0.22
Mean stent area, mm ²	8.0 ± 2.7	7.8 ± 2.1	7.8 ± 2.1	8.3 ± 2.3	0.67
Mean stent expansion, mm ²	110.6 ± 30.8	108.1 ± 24.8	100.9 ± 24.1	105.1 ± 22.0	0.36
Any malapposition strut, %	1.9 ± 2.5	3.0 ± 3.5	4.8 ± 6.2	5.2 ± 4.5	<0.0001

Consistent outcomes regardless of calcium angle



Conclusions

- OCT demonstrated consistent MSA and stent expansion outcomes in eccentric and concentric calcium
- Increased IVL-induced calcium fracture was observed in proportion to the amount of calcium
- Consistent MSA and stent expansion outcomes were observed regardless of the presence of visible calcium fracture
 - Micro-CT imaging suggests OCT may not detect subtle micro-fractures in calcific plaque

